(NASDAQ: IOVA) Iovance Biotherapeutics's forecast annual revenue growth rate of 49.82% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.48%, and while it is forecast to beat the US market's average forecast revenue growth rate of 24.03%.
Iovance Biotherapeutics's revenue in 2026 is $250,425,000.On average, 13 Wall Street analysts forecast IOVA's revenue for 2026 to be $165,257,765,911, with the lowest IOVA revenue forecast at $132,269,727,604, and the highest IOVA revenue forecast at $225,247,565,537. On average, 10 Wall Street analysts forecast IOVA's revenue for 2027 to be $252,233,448,138, with the lowest IOVA revenue forecast at $178,953,160,876, and the highest IOVA revenue forecast at $322,345,930,999.
In 2028, IOVA is forecast to generate $332,845,733,806 in revenue, with the lowest revenue forecast at $227,581,737,201 and the highest revenue forecast at $400,540,681,730.